How Much Can Merck's Share Price Grow If Keytruda Gets 10% Share Of Oncology Drug Market?

Merck's (NYSE:MRK) Keytruda has been on a strong run with sales exceeding $7 billion in 2018. This can be attributed to its superior benefits in lung cancer, and various regulatory approvals for multiple indications. While the drug's peak sales are touted to be as high as $16 billion, we forecast...